中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

100 records (took 0.022 seconds)

    Combination pro/supination and flexion therapeutic mobilization device
    1.
    发明申请
    Combination pro/supination and flexion therapeutic mobilization device 有权
    组合pro / supination和屈曲治疗动员装置

    公开(公告)号：US20040082885A1

    公开(公告)日：2004-04-29

    申请号：US10436465

    申请日：2003-05-13

    Applicant: Orthologic Corp.

    Inventor： Jeff Culhane ,  Alex Solomon ,  Paul Kruger ,  Dragan Milosavljevic ,  Dan Cotterell ,  Andrew MacPhail

    IPC: A61H001/02

    CPC classification number: A61H1/0277 ,  A61H2001/0203 ,  A61H2001/0207 ,  A61H2201/0173 ,  A61H2201/018

    Abstract: A therapeutic mobilization device is disclosed. The device includes a flexion assembly, a pro/supination assembly and a valgus carrying angle compensation device. The flexion assembly has an arm attachment assembly and an elbow actuator and the elbow actuator defines and axes of rotation. The pro/supination assembly is attached to flexion assembly and has a distal forearm attachment assembly and a pro/supination actuator operably connected thereto. The valgus carrying angle compensation device is operably attached to the flexion assembly and the pro/supination assembly. Preferably the pro/supination assembly is slidably mounted on a housing shaft whereby during flexion the pro/supination assembly is free to move along the housing shaft. Further, preferably the arm attachment assembly includes an attachment ring and an adjustable clamp pivotally attached thereto whereby the attachment ring defines a pro/supination axis and the adjustable clamp pivots orthogonally to the pro/supination axis.

    Abstract translation: 公开了一种治疗动员装置。 该装置包括一个屈曲组件，一个推进组件和外翻角度补偿装置。 弯曲组件具有臂附接组件和弯头致动器，并且弯头致动器限定旋转轴。 推进组件附接到屈曲组件并且具有远程前臂附接组件和可操作地连接到其上的推进/推进致动器。 外翻角度补偿装置可操作地附接到屈曲组件和推进组件。 优选地，推进组件可滑动地安装在壳体轴上，由此在弯曲期间，推进组件可自由地沿壳体轴移动。 此外，优选地，臂附接组件包括附接环和可枢转地附接到其上的可调节夹具，由此附接环限定了主轴/仰角轴线，并且可调节的夹具正转地与前/后轴线枢转。

    THROMBIN DERIVED PEPTIDES FOR SMOOTH MUSCLE RELAXATION
    5.
    发明申请
    THROMBIN DERIVED PEPTIDES FOR SMOOTH MUSCLE RELAXATION 审中-公开
    用于SMOOTH肌肉放松的THROMBIN衍生肽

    公开(公告)号：WO2009120304A1

    公开(公告)日：2009-10-01

    申请号：PCT/US2009/001819

    申请日：2009-03-24

    Applicant: ORTHOLOGIC CORP. ,  THE TEXAS A&M UNIVERSITY SYSTEM ,  CARNEY, Darrell, H. ,  OLSZEWSKA-PAZDRAK, Barbara ,  FOSSUM, Theresa, W.

    Inventor： CARNEY, Darrell, H. ,  OLSZEWSKA-PAZDRAK, Barbara ,  FOSSUM, Theresa, W.

    IPC: A61K38/48 ,  A61P21/02

    CPC classification number: A61K38/4833

    Abstract: Agonists of a non-proteolytically activated thrombin receptor, and more particularly, thrombin peptide derivatives, can be used in methods to cause smooth muscle relaxation. Compositions comprising thrombin peptide derivatives can be administered to a subject with a disease or disorder that can be ameliorated by relaxation of smooth muscle. Such compositions can also be administered to a subject to facilitate medical, diagnostic or surgical procedures.

    Abstract translation: 非蛋白水解活化的凝血酶受体的激动剂，更具体地，凝血酶肽衍生物，可以用于引起平滑肌松弛的方法。 可以将包含凝血酶肽衍生物的组合物施用于可通过松弛平滑肌而改善的疾病或病症的受试者。 也可以将这样的组合物施用于受试者以促进医学，诊断或外科手术。

    METHOD OF TREATING DEGENERATIVE DISEASES
    7.
    发明申请
    METHOD OF TREATING DEGENERATIVE DISEASES 审中-公开
    治疗退行性疾病的方法

    公开(公告)号：WO2009120300A3

    公开(公告)日：2009-11-26

    申请号：PCT/US2009001813

    申请日：2009-03-24

    Applicant: ORTHOLOGIC CORP ,  CARNEY DARRELL H ,  STEER RANDOLPH C

    Inventor： CARNEY DARRELL H ,  STEER RANDOLPH C

    IPC: A61K38/48 ,  A61P17/00 ,  A61P25/16 ,  A61P25/28 ,  A61P27/06

    CPC classification number: A61K38/4833

    Abstract: Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy.

    Abstract translation: 非蛋白水解活化受体的激动剂可用于治疗受试者的疾病或病症的方法。 所述方法包括向受试者施用治疗有效量的激动剂，其中所述疾病或病症是硬皮病，黄斑变性，糖尿病性视网膜病变，亨廷顿舞蹈病，帕金森病，闭合性头部创伤，青光眼，视神经炎或同种异体移植血管病变。

    METHOD OF TREATING PERIPHERAL ARTERIAL DISEASE
    8.
    发明申请
    METHOD OF TREATING PERIPHERAL ARTERIAL DISEASE 审中-公开
    治疗周围动脉疾病的方法

    公开(公告)号：WO2009120307A3

    公开(公告)日：2009-11-19

    申请号：PCT/US2009001822

    申请日：2009-03-24

    Applicant: ORTHOLOGIC CORP ,  TEXAS A & M UNIV SYS ,  CARNEY DARRELL H ,  OLSZEWSKA-PAZDRAK BARBARA ,  FOSSUM THERESA W

    Inventor： CARNEY DARRELL H ,  OLSZEWSKA-PAZDRAK BARBARA ,  FOSSUM THERESA W

    IPC: A61K38/04 ,  A61K38/16 ,  A61P9/10

    CPC classification number: A61K38/04 ,  A61K38/16

    Abstract: An agonist of a non-proteolytically activated thrombin receptor can be used in a method for treating peripheral arterial disease. The agonist can be a thrombin peptide derivative. In some embodiments, the peripheral arterial disease is characterized by intermittent claudication. The thrombin peptide derivatives to be used in the methods can have amino acid sequences similar to a region of thrombin. Usually, the thrombin peptide derivatives are 12-23 amino acid residues in length. In some cases, the thrombin peptide derivatives are dimers, and in particular, dimers that result from formation of a disulfide bond between two cysteine residues of peptide monomers.

    Abstract translation: 非蛋白水解活化的凝血酶受体激动剂可用于治疗外周动脉疾病的方法中。 激动剂可以是凝血酶肽衍生物。 在一些实施方案中，外周动脉疾病的特征在于间歇性跛行。 用于该方法的凝血酶肽衍生物可具有与凝血酶区域相似的氨基酸序列。 通常，凝血酶肽衍生物的长度为12-23个氨基酸残基。 在一些情况下，凝血酶肽衍生物是二聚体，特别是由肽单体的两个半胱氨酸残基之间形成二硫键而产生的二聚体。

    METHOD OF TREATING PERIPHERAL ARTERIAL DISEASE
    9.
    发明申请
    METHOD OF TREATING PERIPHERAL ARTERIAL DISEASE 审中-公开
    治疗外周动脉疾病的方法

    公开(公告)号：WO2009120307A2

    公开(公告)日：2009-10-01

    申请号：PCT/US2009/001822

    申请日：2009-03-24

    Applicant: ORTHOLOGIC CORP. ,  THE TEXAS A&M UNIVERSITY SYSTEM ,  CARNEY, Darrell, H. ,  OLSZEWSKA-PAZDRAK, Barbara ,  FOSSUM, Theresa, W.

    Inventor： CARNEY, Darrell, H. ,  OLSZEWSKA-PAZDRAK, Barbara ,  FOSSUM, Theresa, W.

    IPC: A61K38/04 ,  A61K38/16 ,  A61P9/10

    CPC classification number: A61K38/04 ,  A61K38/16

    Abstract: An agonist of a non-proteolytically activated thrombin receptor can be used in a method for treating peripheral arterial disease. The agonist can be a thrombin peptide derivative. In some embodiments, the peripheral arterial disease is characterized by intermittent claudication. The thrombin peptide derivatives to be used in the methods can have amino acid sequences similar to a region of thrombin. Usually, the thrombin peptide derivatives are 12-23 amino acid residues in length. In some cases, the thrombin peptide derivatives are dimers, and in particular, dimers that result from formation of a disulfide bond between two cysteine residues of peptide monomers.

    Abstract translation: 非蛋白水解活化凝血酶受体的激动剂可用于治疗外周动脉疾病的方法。 激动剂可以是凝血酶肽衍生物。 在一些实施方案中，外周动脉疾病的特征在于间歇性跛行。 用于该方法的凝血酶肽衍生物可以具有与凝血酶区域相似的氨基酸序列。 通常，凝血酶肽衍生物的长度为12-23个氨基酸残基。 在一些情况下，凝血酶肽衍生物是二聚体，特别是由肽单体的两个半胱氨酸残基之间形成二硫键导致的二聚体。

    METHOD OF TREATING DEGENERATIVE DISEASES
    10.
    发明申请
    METHOD OF TREATING DEGENERATIVE DISEASES 审中-公开
    治疗退行性疾病的方法

    公开(公告)号：WO2009120300A2

    公开(公告)日：2009-10-01

    申请号：PCT/US2009/001813

    申请日：2009-03-24

    Applicant: ORTHOLOGIC CORP. ,  CARNEY, Darrell, H. ,  STEER, Randolph, C.

    Inventor： CARNEY, Darrell, H. ,  STEER, Randolph, C.

    IPC: A61K38/48 ,  A61P25/16 ,  A61P27/02

    CPC classification number: A61K38/4833

    Abstract: Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy.

    Abstract translation: 非蛋白水解活化的受体的激动剂可用于治疗受试者的疾病或病症的方法中。 所述方法包括向所述受试者施用治疗有效量的激动剂，其中所述疾病或病症为硬皮病，黄斑变性，糖尿病性视网膜病，亨廷顿病，帕金森病，闭合性头部创伤，青光眼，视神经炎或同种异体移植血管病。 >

Patent Agency Ranking